Substituted benzopyran derivatives for the treatment of inflammation

1. A compound of Formula I′

wherein X is NR a ;

wherein R a is selected from hydrido, C 1 –C 3 -alkyl, (optionally substituted phenyl)-C 1 –C 3 -alkyl, acyl and carboxy-C 1 –C 6 -alkyl;

wherein R is selected from carboxyl, aminocarbonyl, C 1 –C 6 -alkylsulfonylaminocarbonyl and C 1 –C 6 -alkoxycarbonyl;

wherein R″ is selected from hydrido, phenyl, thienyl and C 2 –C 6 -alkenyl;

wherein R 1 is selected from C 1 –C 3 -perfluoroalkyl, chloro, C 1 –C 6 -alkylthio, C 1 –C 6 -alkoxy, nitro, cyano and cyano-C 1 –C 3 -alkyl;

wherein R 2 is one or more radicals independently selected from hydrido, halo, C 1 –C 6 -alkyl, C 2 –C 6 -alkenyl, C 2 –C 6 -alkynyl, halo-C 2 –C 6 -alkynyl, aryl-C 1 –C 3 -alkyl, aryl-C 2 –C 6 -alkynyl, aryl-C 2 –C 6 -alkenyl, C 1 –C 6 -alkoxy, methylenedioxy, C 1 –C 6 -alkylthio, C 1 –C 6 -alkylsulfinyl, aryloxy, arylthio, arylsulfinyl, heteroaryloxy, C 1 –C 6 -alkoxy-C 1 –C 6 -alkyl, aryl-C 1 –C 6 -alkyloxy, heteroaryl-C 1 –C 6 -alkyloxy, aryl-C 1 –C 6 -alkoxy-C 1 –C 6 -alkyl, C 1 –C 6 -haloalkyl, C 1 –C 6 -haloalkoxy, C 1 –C 6 -haloalkylthio, C 1 –C 6 -haloalkylsulfinyl, C 1 –C 6 -haloalkylsulfonyl, C 1 –C 3 -(haloalkyl-C 1 –C 3 -hydroxyalkyl, C 1 –C 6 -hydroxyalkyl, hydroxyimino-C 1 –C 6 -alkyl, C 1 –C 6 -alkylamino, arylamino, aryl-C 1 –C 6 -alkylamino, heteroarylamino, heteroaryl-C 1 –C 6 -alkylamino, nitro, cyano, amino, aminosulfonyl, C 1 –C 6 -alkylaminosulfonyl, arylaminosulfonyl, heteroarylaminosulfonyl, aryl-C 1 –C 6 -alkylaminosulfonyl, heteroaryl-C 1 –C 6 -alkylaminosulfonyl, heterocyclylsulfonyl, C 1 –C 6 -alkylsulfonyl, aryl-C 1 –C 6 -alkylsulfonyl, optionally substituted aryl, optionally substituted heteroaryl, aryl-C 1 –C 6 -alkylcarbonyl, heteroaryl-C 1 –C 6 -alkylcarbonyl, heteroarylcarbonyl, arylcarbonyl, aminocarbonyl, C 1 –C 6 -alkoxycarbonyl, formyl, C 1 –C 6 -haloalkylcarbonyl and C 1 –C 6 -alkylcarbonyl; and

wherein the A ring atoms A 1 , A 2 , A 3 and A 4 are independently selected from carbon and nitrogen with the proviso that at least two of A 1 , A 2 , A 3 and A 4 are carbon;

or wherein R 2 together with ring A forms a radical selected from naphthyl, quinolyl, isoquinolyl, quinolizinyl, quinoxalinyl and dibenzofuryl;

or an isomer or pharmaceutically acceptable salt thereof.

2. A compound of claim 1 wherein X is NR a ; wherein R a is selected from hydrido, C 1 –C 3 -alkyl, (optionally substituted phenyl)-C 1 –C 3 -alkyl, acyl and carboxy-C 1 –C 6 -alkyl; wherein R is selected from carboxyl, aminocarbonyl, C 1 –C 6 -alkylsulfonylaminocarbonyl and C 1 –C 6 -alkoxycarbonyl; wherein R″ is selected from hydrido, phenyl, thienyl and C 2 –C 6 -alkenyl; wherein R 1 is selected from C 1 –C 3 -perfluoroalkyl, chloro, C 1 –C 6 -alkylthio, C 1 –C 6 -alkoxy, nitro, cyano and cyano-C 1 –C 3 -alkyl; wherein R 2 is one or more radicals independently selected from hydrido, halo, C 1 –C 6 -alkyl, C 2 –C 6 -alkenyl, C 2 –C 6 -alkynyl, halo-C 2 –C 6 -alkynyl, aryl-C 1 –C 3 -alkyl, aryl-C 2 –C 6 -alkynyl, aryl-C 2 –C 6 -alkenyl, C 1 –C 6 -alkoxy, methylenedioxy, C 1 –C 6 -alkylthio, C 1 –C 6 -alkylsulfinyl, aryloxy, arylthio, arylsulfinyl, heteroaryloxy, C 1 –C 6 -alkoxy-C 1 –C 6 -alkyl, aryl-C 1 –C 6 -alkyloxy, heteroaryl-C 1 –C 6 -alkyloxy, aryl-C 1 –C 6 -alkoxy-C 1 –C 6 -alkyl, C 1 –C 6 -haloalkyl, C 1 –C 6 -haloalkoxy, C 1 –C 6 -haloalkylthio, C 1 –C 6 -haloalkylsulfinyl, C 1 –C 6 -haloalkylsulfonyl, C 1 –C 3 -(haloalkyl-C 1 –C 3 -hydroxyalkyl, C 1 –C 6 -hydroxyalkyl, hydroxyimino-C 1 –C 6 -alkyl, C 1 –C 6 -alkylamino, arylamino, aryl-C 1 –C 6 -alkylamino, heteroarylamino, heteroaryl-C 1 –C 6 -alkylamino, nitro, cyano, amino, aminosulfonyl, C 1 –C 6 -alkylaminosulfonyl, arylaminosulfonyl, heteroarylaminosulfonyl, aryl-C 1 –C 6 -alkylaminosulfonyl, heteroaryl-C 1 –C 6 -alkylaminosulfonyl, heterocyclylsulfonyl, C 1 –C 6 -alkylsulfonyl, aryl-C 1 –C 6 -alkylsulfonyl, optionally substituted aryl, optionally substituted heteroaryl, aryl-C 1 –C 6 -alkylcarbonyl, heteroaryl-C 1 –C 6 -alkylcarbonyl, heteroarylcarbonyl, arylcarbonyl, aminocarbonyl, C 1 –C 6 -alkoxycarbonyl, formyl, C 1 –C 6 -haloalkylcarbonyl and C 1 –C 6 -alkylcarbonyl; and wherein the A ring atoms A 1 , A 2 , A 3 and A 4 are independently selected from carbon and nitrogen with the proviso that at least three of A 1 , A 2 , A 3 and A 4 are carbon; or wherein R 2 together with ring A forms a naphthyl or quinolyl radical; or an isomer or pharmaceutically acceptable salt thereof.

3. A compound of claim 2 wherein X is NR a ; wherein R a is selected from hydrido, C 1 –C 3 -alkyl and (optionally substituted phenyl)methyl; wherein R is carboxyl; wherein R″ is selected from hydrido and C 2 –C 6 -alkenyl; wherein R 1 is selected from C 1 –C 3 -perfluoroalkyl; wherein R 2 is one or more radicals independently selected from hydrido, halo, C 1 –C 6 -alkyl, C 2 –C 6 -alkenyl, C 2 –C 6 -alkynyl, halo-C 2 –C 6 -alkynyl, phenyl-C 1 –C 6 -alkyl, phenyl-C 2 –C 6 -alkynyl, phenyl-C 2 –C 6 -alkenyl, C 1 –C 3 -alkoxy, methylenedioxy, C 1 –C 3 -alkoxy-C 1 –C 3 -alkyl, C 1 –C 3 -alkylthio, C 1 –C 3 -alkylsulfinyl, phenyloxy, phenylthio, phenylsulfinyl, C 1 –C 3 -haloalkyl-C 1 –C 3 -hydroxyalkyl, phenyl-C 1 –C 3 -alkyloxy-C 1 –C 3 -alkyl, C 1 –C 3 -haloalkyl, C 1 –C 3 -haloalkoxy, C 1 –C 3 -haloalkylthio, C 1 –C 3 -hydroxyalkyl, C 1 –C 3 -alkoxy-C 1 –C 3 -alkyl, hydroxyimino-C 1 –C 3 -alkyl, C 1 –C 6 -alkylamino, nitro, cyano, amino, aminosulfonyl, N-alkylaminosulfonyl, N-arylaminosulfonyl, N-heteroarylaminosulfonyl, N-(phenyl-C 1 –C 6 -alkyl)aminosulfonyl, N-(heteroaryl-C 1 –C 6 -alkyl)aminosulfonyl, phenyl-C 1 –C 3 -alkylsulfonyl, 5- to 8-membered heterocyclylsulfonyl, C 1 –C 6 -alkylsulfonyl, optionally substituted phenyl, optionally substituted 5- to 9-membered heteroaryl, phenyl-C 1 –C 6 -alkylcarbonyl, phenylcarbonyl, 4-chlorophenylcarbonyl, 4-hydroxyphenylcarbonyl, 4-trifluoromethylphenylcarbonyl, 4-methoxyphenylcarbonyl, aminocarbonyl, formyl, and C 1 –C 6 -alkylcarbonyl; wherein the A ring atoms A 1 , A 2 , A 3 and A 4 are independently selected from carbon and nitrogen with the proviso that at least three of A 1 , A 2 , A 3 and A 4 are carbon; or wherein R 2 together with ring A forms a naphthyl, benzofurylphenyl, or quinolyl radical; or an isomer or pharmaceutically acceptable salt thereof.

4. A compound of claim 3 wherein X is NR a ; wherein R a is selected from hydrido, methyl, ethyl, (4-trifluoromethyl)benzyl, (4-chloromethyl)benzyl, (4-methoxy)benzyl, and (4-cyano)benzyl, (4-nitro)benzyl; wherein R is carboxyl; wherein R″ is selected from hydrido and ethenyl; wherein R 1 is selected from trifluoromethyl and pentafluoroethyl; wherein R 2 is one or more radicals independently selected from hydrido, chloro, bromo, fluoro, iodo, methyl, tert-butyl, ethenyl, ethynyl, 5-chloro-1-pentynyl, 1-pentynyl, 3,3-dimethyl-1-butynyl, benzyl, phenylethyl, phenyl-ethynyl, 4-chlorophenyl-ethynyl, 4-methoxyphenyl-ethynyl, phenylethenyl, methoxy, methylthio, methylsulfinyl, phenyloxy, phenylthio, phenylsulfinyl, methylenedioxy, benzyloxymethyl, trifluoromethyl, difluoromethyl, pentafluoroethyl, trifluoromethoxy, trifluoromethylthio, hydroxymethyl, hydroxy-trifluoroethyl, methoxymethyl, hydroxyiminomethyl, N-methylamino, nitro, cyano, amino, aminosulfonyl, N-methylaminosulfonyl, N-phenylaminosulfonyl, N-furylaminosulfonyl, N-(benzyl)aminosulfonyl, N-(furylmethyl)aminosulfonyl, benzylsulfonyl, phenylethylaminosulfonyl, furylsulfonyl, methylsulfonyl, phenyl, phenyl substituted with one or more radicals selected from chloro, fluoro, bromo, methoxy, methylthio and methylsulfonyl, benzimidazolyl, thienyl, thienyl substituted with chloro, furyl, furyl substituted with chloro, benzylcarbonyl, optionally substituted phenylcarbonyl, aminocarbonyl, formyl and methylcarbonyl; wherein the A ring atoms A 1 , A 2 , A 3 and A 4 are independently selected from carbon and nitrogen with the proviso that at least three of A 1 , A 2 , A 3 and A 4 are carbon; or wherein R 2 together with ring A forms a naphthyl, or quinolyl radical; or an isomer or pharmaceutically acceptable salt thereof.

5. A compound of claim 2 wherein X is NR a ; wherein R a is selected from hydrido, C 1 –C 3 -alkyl, phenyl-C 1 –C 3 -alkyl, acyl and carboxy-C 1 –C 3 -alkyl; wherein R is carboxyl; wherein R 1 is selected from C 1 –C 3 -perfluoroalkyl; wherein R 2 is one or more radicals independently selected from hydrido, halo, C 1 –C 6 -alkyl, phenyl-C 1 –C 6 -alkyl, phenyl-C 2 –C 6 -alkynyl, phenyl-C 2 –C 6 -alkenyl, C 1 –C 6 -alkoxy, phenyloxy, 5- or 6-membered heteroaryloxy, phenyl-C 1 –C 6 -alkyloxy, 5- or 6-membered heteroaryl-C 1 –C 6 -alkyloxy, C 1 –C 6 -haloalkyl, C 1 –C 6 -haloalkoxy, C 1 –C 6 -alkylamino, N-phenylamino, N-(phenyl-C 1 –C 6 -alkyl)amino, N-heteroarylamino, N-(heteroaryl-C 1 –C 6 -alkylamino, nitro, amino, aminosulfonyl, N-alkylaminosulfonyl, N-arylaminosulfonyl, N-heteroarylaminosulfonyl, N-(phenyl-C 1 –C 6 -alkyl)aminosulfonyl, N-(heteroaryl-C 1 –C 6 -alkyl)aminosulfonyl, 5- to 8-membered heterocyclylsulfonyl, C 1 –C 6 -alkylsulfonyl, optionally substituted phenyl, optionally substituted 5- or 6-membered heteroaryl, phenyl-C 1 –C 6 -alkylcarbonyl, heteroarylcarbonyl, phenylcarbonyl, aminocarbonyl, and C 1 –C 6 -alkylcarbonyl; wherein the A ring atoms A 1 , A 2 , A 3 and A 4 are independently selected from carbon and nitrogen with the proviso that at least three of A 1 , A 2 , A 3 and A 4 are carbon; or an isomer or pharmaceutically acceptable salt thereof.

6. A compound of claim 5 wherein X is NR a ; wherein R a is selected from hydrido, methyl, ethyl, (4-trifluoromethyl)benzyl, (4-chloromethyl)benzyl, (4-methoxy)benzyl, (4-cyano)benzyl, and (4-nitro)benzyl; wherein R is carboxyl; wherein R″ is selected from hydrido and ethenyl; wherein R 1 is selected from trifluoromethyl and pentafluoroethyl; wherein R 2 is one or more radicals independently selected from hydrido, chloro, bromo, fluoro, iodo, methyl, tert-butyl, ethenyl, ethynyl, 5-chloro-1-pentynyl, 1-pentynyl, 3,3-dimethyl-1-butynyl, benzyl, phenylethyl, phenyl-ethynyl, 4-chlorophenyl-ethynyl, 4-methoxyphenyl-ethynyl, phenylethenyl, methoxy, methylthio, methylsulfinyl, phenyloxy, phenylthio, phenylsulfinyl, pyridyloxy, thienyloxy, furyloxy, phenylmethoxy, methylenedioxy, benzyloxymethyl, trifluoromethyl, difluoromethyl, pentafluoroethyl, trifluoromethoxy, trifluoromethylthio, hydroxymethyl, hydroxy-trifluoroethyl, methoxymethyl, hydroxyiminomethyl, N-methylamino, N-phenylamino, N-(benzyl)amino, nitro, cyano, amino, aminosulfonyl, N-methylaminosulfonyl, N-phenylaminosulfonyl, N-furylaminosulfonyl, N-(benzyl)aminosulfonyl, N-(furylmethyl)aminosulfonyl, benzylsulfonyl, phenylethylaminosulfonyl, furylsulfonyl, methylsulfonyl, phenyl, phenyl substituted with one or more radicals selected from chloro, fluoro, bromo, methoxy, methylthio and methylsulfonyl, benzimidazolyl, thienyl, thienyl substituted with chloro, furyl, furyl substituted with chloro, benzylcarbonyl, furylcarbonyl, phenylcarbonyl, aminocarbonyl, formyl, and methylcarbonyl; wherein the A ring atoms A 1 , A 2 , A 3 and A 4 are carbon; or an isomer or pharmaceutically acceptable salt thereof.

7. A compound of claim 6 selected from compounds, and their isomers and pharmaceutically-acceptable salts, of the group consisting of

6-chloro-1,2-dihydro-2-(trifluoromethyl)-3-quinolinecarboxylic acid;

6,8-dichloro-1,2-dihydro-2-(trifluoromethyl)-3-quinolinecarboxylic acid;

6,7-difluoro-1,2-dihydro-2-(trifluoromethyl)-3-quinolinecarboxylic acid;

6-iodo-1,2-dihydro-2-(trifluoromethyl)-3-quinolinecarboxylic acid;

6-bromo-1,2-dihydro-2-(trifluoromethyl)-3-quinolinecarboxylic acid;

1,2-dihydro-6-(trifluoromethoxy)-2-(trifluoromethyl)-3-quinolinecarboxylic acid;

6-(trifluoromethyl)-1,2-dihydro-2-(trifluoromethyl)-3-quinolinecarboxylic acid;

6-cyano-1,2-dihydro-2-(trifluoromethyl)-3-quinolinecarboxylic acid;

6-chloro-1,2-dihydro-1-methyl-2-(trifluoromethyl)-3-quinolinecarboxylic acid;

6-chloro-1,2-dihydro-2-(trifluoromethyl)-1-[[4-(trifluoromethyl)phenyl]methyl]-3-quinolinecarboxylic acid;

6-chloro-1-[(4-chlorophenyl)methyl]-1,2-dihydro-2-(trifluoromethyl)-3-quinolinecarboxylic acid;

6-chloro-1,2-dihydro-2-(trifluoromethyl)-1-[[4-(methoxy)phenyl]methyl]-3-quinolinecarboxylic acid;

6-chloro-1-[(4-cyanophenyl)methyl]-1,2-dihydro-2-(trifluoromethyl)-3-quinolinecarboxylic acid;

6-chloro-1,2-dihydro-1-[(4-nitrophenyl)methyl]-2-(trifluoromethyl)-3-quinolinecarboxylic acid;

6-chloro-1,2-dihydro-1-ethyl-2-(trifluoromethyl)-3-quinolinecarboxylic acid; and

(S)-6-chloro-1,2-dihydro-2-(trifluoromethyl)-3-quinolinecarboxylic acid.

8. A compound of Formula IIc:

wherein R a is selected from hydrido and lower aralkyl; wherein R 3 is selected from hydrido, lower alkyl, lower hydroxyalkyl, lower alkoxy and halo; wherein R 4 is selected from hydrido, halo, lower alkyl, lower alkylthio, lower haloalkyl, amino, aminosulfonyl, lower alkylsulfonyl, lower alkylsulfinyl, lower alkoxyalkyl, lower alkylcarbonyl, formyl, cyano, lower haloalkylthio, substituted or unsubstituted phenylcarbonyl, lower haloalkoxy, lower alkoxy, lower aralkylcarbonyl, lower dialkylaminosulfonyl, lower alkylaminosulfonyl, lower aralkylaminosulfonyl, lower heteroaralkylaminosulfonyl, 5- or 6-membered heteroaryl, lower hydrooxyalkyl, optionally substituted phenyl and 5- or 6-membered nitrogen containing heterocyclosulfonyl; wherein R 5 is selected from hydrido, lower alkyl, halo, lower haloalkyl, lower alkoxy, and phenyl; and wherein R 6 is selected from hydrido, halo, cyano, hydrooxyiminomethyl, lower hydroxyalkyl, lower alkynyl, phenylalkynyl, lower alkyl, lower alkoxy, formyl and phenyl;

or an isomer or pharmaceutically acceptable salt thereof.

9. A pharmaceutical composition comprising a therapeutically-effective amount of a compound, said compound selected from a family of compounds of claims 1 – 4 , 5 – 7 and 8 ; or a pharmaceutically-acceptable salt thereof.